Our website is made possible by displaying non-intrusive online advertisements to our visitors.
Please consider supporting us by disabling or pausing your ad blocker.
For the period under review , Group revenue has been increased by 12.72% (or RM3.18 million) from RM 24.98 million to RM 28.15 million due to increasing sales from existing customers of subsidiaries. The profit after tax increased by 9.34 % ( or RM 0.35 million) from RM 3.75 million due to contribution from unrealised gain on foreign exchange. The Supercomal Medical Products (SMP) contributed 87% of the group profit.
There is no major impact to the Group in terms of its ability to operate during the MCO because the Group has obtained approval from Ministry of International Trade and Industry (“MITI”) to operate during the MCO period. This approval from MITI allowed the Group to operate with a headcount of 220 employees with effect from March 18, 2020 to March 31, 2020, a headcount of 273 employees with effect from April 1, 2020 to April 14, 2020, a headcount of 356 employees
Agreed with KLSE Commentor, this is the pre C19 performance and can be considered a good result. Please bear in mind, this is a delayed results and the current health care sentiments are not that hot as compared to couple of weeks back. Next few quarters result will reflect C19 full demand of the company products. Moving forward, key catalyst to monitor:
1. C19 infection rate, possibly of wave 2 or the virus will fade off naturally ?
The qr overall is quite good and increased NTA as well. However, unless there is any positive news to push this price further up, otherwise i guess will hang around this price range unless somewhere in next qr
Short term price fluctuation are expected as some might take this opportunity to take profit and some will capitalize on this profit taking session to buy more when price comes down. Overall, is a good company with strong fundamentals, growing business and most importantly, debt free. Have your own investment plan and all the best.
